Plain-English translation of NCT07407933 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new drug called combined with an immunotherapy called for people with advanced small cell lung cancer. Researchers want to find the right dose of this medication that works best and has manageable side effects. The trial will first test different dose levels to see which is safest, then expand to treat more patients at the best dose.
Small cell lung cancer is an aggressive disease, and people with advanced stages need better treatment options. This medication is designed to work in a new way to fight cancer cells, and combining it with immunotherapy may help patients live longer and with better quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the two medications every three weeks. The study has two parts: first, researchers will test different doses in a smaller group to find the safest level; then they will expand to treat more patients at the dose that worked best. You would visit the clinic regularly for blood tests, scans, and check-ups, and continue treatment until your cancer stops responding, side effects become too difficult to manage, or you decide to stop.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States